NEW YORK (GenomeWeb News) - LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said today.
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights.
The license will allow LabCorp to offer the test, which is registered as an IVD in Europe, through its CLIA-registered US labs.
The company said that a “high proportion” of individuals with myeloproliferative disorders have a dominant mutation of the JAK2 gene.
Financial terms of the agreement were not released.
Last month, Ispogen granted Warnex rights to offer the JAK2 assay in Canada.